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Background: The prevalence of chronic venous disease is high and occurs more frequently in females. According
to the clinical, etiological, anatomical, and pathological classification (CEAP) definition, the reticular veins are
included in the C1 class and are mainly associated with aesthetic complaints. Several invasive techniques are used
for treatment, including mini phlebectomy, laser ablation, and radiofrequency ablation. However, a wide range of
sclerosing agents may serve as minimally invasive alternatives, promoting chemical sclerosis of the vein wall.
Although this technique is routinely performed around the world, there is no consensus on the most efficacious
and safe chemical agent to be used.
Methods/design: Inclusion criteria are women between 18 and 69 years old with at least 10 cm long reticular
veins in the lower limbs, on the outer side of the leg/thigh. Patients with CEAP 2 to 6, or with allergies, pregnancy,
performing breastfeeding, or with any dermatologic or clinical problems will be excluded. Patients with venous
ultrasound mapping showing involvement of saphenous trunks and/or a deep venous system will also be
excluded. Patients will be randomized into two groups, one receiving 75% pure glucose and the other group
receiving 0.2% polidocanol diluted in 70% glucose. Just one limb and one session per patient will be performed.
The sclerosing agent volume will not exceed 5 mL. Clinical follow-up will include visits on days 7 and 60, always
with photographic documentation.
Discussion: This project aims to enroll 96 patients and subject them to a double-blind treatment after the
randomization process. The design is intended to evaluate efficacy through a primary end point and safety through
a secondary end point. Forty-eight patients have currently been enrolled. Preliminary results for these patients
showed that 25 received treatment, 2 were excluded, and 22 returned after 7 days and showed no greater adverse
events. To date, establishing efficacy criteria has not been possible, and no patients have reached the 60-day return
point. These data may help doctors choose the best chemical agent for the treatment of reticular veins.
Trial registration: ClinicalTrials.gov Identifier: NCT02054325, 3/02/2014.
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According to the definition of the clinical, etiological, ana-
tomical, and pathological classification (CEAP), the reticular
veins are included in the C1 class and are mainly associated
with aesthetic complaints. Several invasive techniques are
commonly used for treatment, including mini phlebectomy,
laser ablation, and radiofrequency ablation. However, a wide
range of sclerosing agents may serve as minimally invasive
alternatives, promoting chemical sclerosis of the vein wall.
Reticular veins have a diameter no greater than 3 mm and
are straight, bluish, and located in the subcutaneous tissue
of the lower limbs [1]. They have the same complex etiology
of all types of primary venous insufficiency such as hormo-
nal issues, family history, and standing position [2,3]. How-
ever, despite its common occurrence, the condition remains
poorly understood [4]. Sclerotherapy is the preferred treat-
ment for some patients because of its simplicity and repro-
ducibility [5,6], and consists of an intraluminal sclerosing
agent application to trigger endothelial injury, with subse-
quent luminal occlusion of these segments. Many agents,
such as hypertonic saline and hypertonic glucose as hyper-
osmolar sclerosing agents, as well as ethamolin® and polido-
canol as detergent agents [5,7], are known to be effective.
Hypertonic osmotic solutions cause dehydration and de-
struction of endothelial cells. Hypertonic dextrose (or glu-
cose) and sodium tetradecyl sulfate are commonly used due
to their low cost and safety [8-10]. Conversely, polidocanol
acts as a detergent on vein wall lipids, destroying the cellular
cement and causing endothelial maceration; this process ef-
fectively occludes the vein [11-14]. Due to its efficacy and
manipulability, the use of polidocanol is quite common
throughout the world. Usually, it is mixed with a wide
variety of diluents, such as distilled water, air, or hypertonic
glucose. However, some collateral damage can occur from
these mixtures, including necrosis, hyperpigmentation
stains, allergic reactions, and systemic disorders. Chest pain,
cough, anaphylaxis, scotoma, and gas embolization are un-
usual, but serious adverse events have already been reported
in other studies due to this agent, although these issues are
commonly related to miscalculated dosages [15-17].
Chemical sclerotherapy is slightly painful and the dis-
comfort is limited to the puncture site, which warrants a
free anesthesia procedure. The procedure is usually well
tolerated by patients and has a rapid recovery period.
However, the use of sclerotherapy for reticular veins is
controversial because of its association with blemishes
and other risks. However, evidence of these risks is
equivocal [2]. Recent studies have shown that various for-
mations of polidocanol are effective in the performance of
sclerotherapy for reticular veins [11]. Results from our
study have shown positive effects in the treatment of re-
ticular veins using a 0.2% polidocanol solution and 70%
hypertonic glucose. Additionally, there was a low occur-
rence of stains and no major collateral effects. The Foodand Drug Administration approved polidocanol as a medi-
cinal sclerosing agent in the United States in 2010, and
was soon followed by several European countries. The for-
mulation of polidocanol described above is available for
sclerotherapy in Brazil despite the lack of appropriate sci-
entific literature on this treatment. Therefore, the aim of
this study is to assess the benefits and safety of a reticular
vein treatment using a formulation of 0.2% polidocanol
with 70% hypertonic glucose in Brazilian patients.
Hypothesis
We hypothesize that 0.2% polidocanol plus 70% hyper-
tonic glucose is superior to 75% hypertonic glucose alone
in promoting the disappearance of reticular veins of the
lower limbs. Moreover, we hypothesize that 0.2% polido-
canol plus 70% hypertonic glucose is not inferior to 75%
hypertonic glucose in terms of safety.
Methods and design
Trial design
This study is a single-center, prospective, randomized,
triple-blind trial to compare the safety and efficacy of two
sclerosing agents (0.2% polidocanol plus 70% hypertonic
glucose versus 75% hypertonic glucose) in women over
60 days.
Patient enrollment and randomization
A convenience sample of patients undergoing treatment
for mild varicose veins will be employed. Patient infor-
mation will be entered into an electronic database, and
participants will later be contacted to attend an out-
patient evaluation. In the first evaluation, patients who
have a reticular vein measuring at least 10 cm long in
the outer-side of the leg and/or thigh will be invited to
join the study. The sample size was estimated to be 96
treated limbs (see “Statistical analyses”). All subjects will
be informed of study risks and will be required to sign
an informed consent form approved by the institutional
review board. The random allocation schedule will be
generated using the computer program Stat Trek
(http://stattrek.com/Tables/Random.aspx).
Two groups will be established for the treatment of reticu-
lar veins, including either 0.2% polidocanol diluted in 70%
glucose or 75% glucose alone. A trained nurse will store all
data and remain in charge of arrangements, such as prepar-
ing the solutions used in the treatments, throughout the
duration of the study. Solutions will be prepared in a specific
room (different from the office) using sterile 10 mL syringes.
Syringes will be identified according to a random number
given to each patient.
Ethics
This trial is being conducted in accordance with the princi-
ples of Helsinki’s Declaration, ISO14155 and Good Clinical
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the Botucatu Medical School, from the Paulista State Uni-
versity, São Paulo State, Brazil, approved this trial, which
was registered under protocol number CEP4127-2012. A
written informed consent was obtained from all subjects
before enrollment. Subjects can withdraw from this trial
whenever at their own discretion, with no prejudice. The
ClinicalTrials.gov identifier for this trial is NCT02054325
and was obtained on February 3, 2014.
Clinical and pre-treatment measures
Patients will be included if they present one or more reticu-
lar veins with a minimal length of 10 cm, and no edema or
palpable tortuosity. A duplex ultrasonography will then be
performed prior to treatment. Clinical data, such as comor-
bidities, demographic features, and other relevant informa-
tion, will be collected for later analysis. All excluded patients
will be referred for other clinical follow-up techniques at the
institution.
Inclusion and exclusion criteria
Inclusion criteria
Women, having one or more reticular veins measuring at
least 10 cm long on the outer side of the leg and/or thigh
with a clinical classification of C1 CEAP [18] (which means
absence of varicose veins), aged between 18 and 69 years,
who agree to the terms of the research, sign the free consent
form, available to make the required appointments neces-
sary for follow-up, consent to avoid pregnancy for at least
three months after the treatment, and do not use anticoagu-
lant drugs (Additional file 1).
Exclusion criteria
Males, females with CEAP 2 to 6 [18], low mobility, periph-
eral arterial disease, known allergy history to the drugs used
in this study (glucose and polidocanol), presence of derma-
titis in the lower limbs and presence of comorbidities (such
as diabetes mellitus, heart failure, respiratory failure, uncon-
trolled hypertension, hypothyroidism or hyperthyroidism),
pregnancy, breastfeeding, pulmonary hypertension, prior
deep venous thrombosis (DVT), familiar history of DVT,
known hypercoagulable states or thrombophilia, asthma,
migraine, or anyone that does not agree with any of the re-
search terms (Additional file 1).
Treatment area
To define the treatment area, on the outer side of the lower
limbs (thigh and leg) and using the fibular head projection
as an anatomical reference point, a longitudinal imaginary
line measuring 25 cm (up) and 15 cm (down) will be drawn
using the fibular head as a starting point. Two additional
lines will be drawn parallel to the first one, with one marked
at 7.5 cm anterior and the other at 7.5 cm posterior, which
define the limited area for treatment (600 cm2; Additionalfile 2). In this area, one or two reticular veins, measuring
from 10 cm to 20 cm in total length, will be treated with a
minimum of 10, and a maximum of 30, punctures and with
5 mL as the maximum volume of medication over the treat-
ment duration. Each puncture will not exceed 0.3 mL of
volume.
Photographic registry
Photos of patients will be taken to register the early and late
results of the treatment area (pre-treatment). A high defin-
ition camera (D7000 Nikon™ Lens: AF-S Nikkor™ 18–
105 mm 1:3.5-5.6G) will be used to obtain these pictures.
The target area, described above, will be photographed be-
fore treatment (pretreatment) to prevent a possible time bias
related to the patient’s illness. Patients will be placed in a
standing position on a platform with the target area facing
the camera, which will be placed 1.0 m away. A high-
definition standardized scale (attached to the platform) will
be used to perform all measurements. The room will be ar-
ranged with ideal lighting.
Pictures will be stored in files for later analysis using
ImageJ™ software. Each photo will be identified with
code numbers (according to the randomized number of
the protocol), matching the moment of the study (Day 0
(D0) and D60). ImageJ software will be used to measure
the length of the treated veins by turning pixels into
centimeters using a 2 cm line drawn upon the standard-
ized scale. Measurements will be taken from the photos
before and after the study.
Treatment (D0)
After the photographs are taken, the two groups will be
treated similarly to eliminate all the reticular veins in the
area of the selected lower limb. All procedures will be per-
formed by the same physician. A rigorous conventional
sclerotherapy technique will be followed, consisting of care-
ful injections to prevent leakage of fluid into the subcutane-
ous tissue. The procedure will be performed until veins
become undetectable. The maximum volume allowed per
puncture will not exceed 1 mL. A 3 mL luer-lok plastic syr-
inge BD® will be used with a 13 × 4 Terumo® needle (27 G1/
2). Bandages will be performed with a cotton ball (approxi-
mately 0.3 cm in diameter) attached to a square piece of
plaster tape (measuring approximately 2 × 3 cm) right after
the completion of the procedure to stop backflow. Before
discharge, the target area will be submitted to elastic com-
pression using a 1.5 m long elastic band (Atadress®) for one
day [19].
All treatment data will be gathered, including the minimal
volume of solution necessary for the whole disappearance of
all the reticular veins in the target area, number of punc-
tures, location of the target area, possible allergic reactions,
and existence of minimum varicose veins in the target area.
Additionally, a form will be given to the patient to fill out to
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(Additional file 3). Patients will be given careful oral and
written instructions on how to proceed after treatment
(Additional file 4). All patients will receive one tube of
cream containing 0.5% sodium heparin to treat any initial
blemishes, to be used twice per day for two weeks.
Post-treatment (D7)
On approximately the seventh day, a new clinical evaluation
will be performed (7 ± 2 days after the treatment session;
D7). At this appointment, early results of the treatment will
be evaluated, focusing on adverse events (minor or major)
such as allergies, edema, respiratory complaints, syncope,
scotoma, suspected DVT, and phlebitis. If identified, these
adverse events will be recorded. Should phlebitis occur, it
will be released with microneedle punctures (13 × 4.5 BD®)
and gentle compression. An image from the target area
will be recorded and placed at the same position as de-
scribed above.
Post-procedure (D60)
After 60 ± 15 days, the last clinical evaluation will be per-
formed. Efficacy issues will be recorded and a new photo
register (from the target area) will be performed, according
to the procedures described above. In addition, any new ad-
verse event that has been reported for the patient or noticed
during the physical examination (allergies, edema, respira-
tory complaints, syncope, scotoma, suspected DVT, phle-
bitis, ulceration) will be registered. In case of phlebitis,
treatment will be the same as described above.
Outcomes
Primary endpoint – efficacy
Analysis of the primary endpoint (efficacy) will be based on
the ability of each treatment to promote the disappearance
of the reticular veins after 60 days of treatment (D60). Effi-
cacy will be scored according to commonly used visual aes-
thetic aspects [2]. Photo analysis will be used to evaluate
efficacy (from D0 to D60), which will be performed by two
external physicians (both vascular surgeons) who are blinded
to treatment modality. According to the image, these judges
will assign scores for each patient as follows: 5 (excellent –
complete healing at the target area); 4 (very good – presence
of up to 1 cm of non-healed veins in length at the target
area); 3 (good – presence of 1 cm to 3 cm of non-healed
veins in length at the target area); 2 (fair – presence of 3 cm
to 5 cm of non-healed veins in length at the target area), 1
(bad – presence of 5 cm to 9 cm of non-healed veins in
length at the target area), and 0 (unsuccessful – presence of
more than 9 cm of non-healed veins in length at the target
area) (Additional file 5). Prior to these analyses, both judges
will be trained with 10 random patients to standardize the
methods of measurement.If there are conflicting results in the scores assigned by
the two judges (divergence in scores up to 1 point), a third
previously trained judge will be assigned to independently
score that image, and the final score will be the average of
the scores from the three judges. However, if there are con-
flicting results in the scores assigned by the two judges
(divergence in scores greater than 2 points), a conference
among the two judges with a third previously trained judge
will be arranged to define a consensus on the final score. All
these procedures will be carried out in a blind manner.Secondary endpoint – safety
Any type of adverse event (major or minor) that arises
through the period of the study (D0 to D60) will be
tracked. Reports, such as pain due to the procedure
(discomfort reported by the patient, caused by needle
punctures, and/or agent indwell), will be evaluated
using the “Patient Satisfaction Questionnaire”. Adverse
events that will be directly analyzed at the secondary
endpoint (Additional file 3) are stains (limited to the
target area), hematomas (limited to the target area),
edema, and phlebitis (limited to the target limb). DVT
is a severe, but unusual, complication with few existing
reports documenting its effects [15]. However, this com-
plication will also be recorded if it occurs. All of these
data will be collected during medical visits (D0 to D60).
The photos taken at the end of the study (D60) will be
used to evaluate irreversible skin changes such as hyper-
pigmentation. Two external physicians (both vascular
surgeons), blinded to which modality of treatment was
carried out, will score the changes as follows: 5 (excel-
lent – no visible hyperpigmentation at the target area);
4 (very good – presence of only one point of hyperpig-
mentation up to 1 cm in length at the target area); 3
(good – presence of 2 to 3 points of hyperpigmentation
up to 1 cm in length at the target area); 2 (fair – pres-
ence of 4 to 5 points of hyperpigmentation up to 1 cm
in length, or one hyperchromatic line, up to 5 cm in
length, at the target area); 1 (bad – presence of more
than 5 points of hyperpigmentation up to 1 cm in
length, or one hyperchromatic line, with more than
5 cm and less than 9 cm in length, at the target area);
and 0 (unsuccessful – presence of a hyperchromatic line
larger than 9 cm in length, or the total extension of the
vein presenting hyperpigmentation, at the target area)
(Additional file 6). Any conflicting results in the scores
assigned by the two judges will be handled as described
in the “Primary endpoint” section above.
Other data will be gathered in the analysis such as demo-
graphic data, skin color, and skin changes at the target area
(pain, phlebitis, stains). Major adverse events, such as deep
venous thrombosis, will also be reported throughout the
study.
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Based on alpha = 0.05, and assuming a standard deviation in
the primary endpoint score of 1.5, with 48 participants in
each arm, we have >80% power to detect a minimal differ-
ence in scores of 0.9. Only one extremity will be included
per patient. It is expected that 10% of patients will be lost
during follow-up. To promote the most statistically rigorous
method, we will use a larger sample size of at least 106 pa-
tients. Data will be evaluated either by Student’s t-test or
non-parametric Mann–Whitney test (if relevant conditions
are not met). Categorical variables (e.g., proportions) will be
compared between groups using the χ2 or Fisher’s exact test
when necessary. Scores between the groups will be
compared with Mann–Whitney test. All statistical analyses
will be performed using STATA® v11 (Stata Corp, College
Station, TX, USA). All analyses will be performed on an
intent-to-treat basis.
Expected adverse effects
Both selected study drugs (75% hypertonic glucose and
0.2% polidocanol) are widely used as sclerosing agents in
aesthetic venous procedures. There are a few reports of
75% hypertonic glucose usage resulting in major compli-
cations. However, polidocanol is associated with some re-
ports of adverse events such as gas embolism and deep
venous thrombosis. Pain, local edema, stains, phlebitis,
and ulcers are minor adverse events related to these
agents. If any other relevant effects occur, they will be re-
ported to the Ethics Committee.
Preliminary results
Forty-eight patients are currently enrolled; 25 patients have
received treatment, 2 patients were excluded due to selec-
tion error, and 22 showed no major adverse effects during
D7. However, the majority of patients had small local
hematoma. Nevertheless, determining the efficacy of the
sclerosing agent is currently not possible, given that no
patient reached D60. We expect to answer some questions
regarding the safety and efficacy of these sclerosing agents,
including the advantages and limitations of each. Finally,
we hope to determine the superiority of one agent over
the other.
Funding
This study has received financial support from “Sao Paulo
Research Foundation – FAPESP”, under protocol number
2012/11034-0.
Discussion
Several studies have shown sclerotherapy to be feasible in
the treatments of reticular veins using various sclerosing
agents [20-22]. However, none has investigated the effects of
polidocanol diluted at 0.2% in 70% glucose when compared
to 75% glucose, commonly used in these procedures. Ourgoal is to compare the safety and efficacy of these two
agents, as well as to determine a possible superiority of one
over the other. Secondary endpoints consist of evaluating
pain triggered by the sclerosant agent, as well as the occur-
rence of adverse events like phlebitis and stains [15]. Add-
itionally, we intend to report the occurrence of “difficult to
treat” hyperchromic stains in patients submitted to this type
of treatment. This information, analyzed judiciously, will
help vascular surgeons and dermatologists choose the best
therapeutic modality.Trial status
This trial has been actively recruiting patients since
September 2013. The completion date for this study is es-
timated as December 2014.Additional files
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Additional file 2: Representative picture of anatomic area of treatment.
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Additional file 4: Instructions for the patient.
Additional file 5: Primary end point. Score of disappearance of reticular
veins treated.
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